Employees: 3,871
Size Vital KSK (3151.T) is a Japan Health Care company (Medical Distributors) with a market value of $399M, the 1182nd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,421 on 18 Nov 2026.
Performance Over six months the shares fell 1.4%, against -5.6% for the median peer and -1.4% for the Japan market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 2.7% over the last twelve months (peer median +3.9%); the operating margin is 0.5% (peer median 2.3%).
Valuation It trades at 0.1× enterprise value to sales against a peer median of 1.2× (cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.2 points below its cost of capital (5.2% WACC).
Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥620B | ¥610B | ¥600B | ¥587B | ¥581B |
| Revenue growth | — | +2% | +2% | +1% | — |
| Gross profit | ¥50.1B | ¥49.6B | ¥49.2B | ¥48.3B | ¥46.5B |
| EBITDA | ¥7.32B | ¥8.08B | ¥9.49B | ¥8.84B | ¥7.38B |
| Net income | ¥2.86B | ¥7.36B | ¥7.31B | ¥5.84B | ¥4.83B |
| Free cash flow | n/a | ¥1.11B | -¥10.6B | ¥21.7B | -¥8.84B |
| Capital expenditure | n/a | ¥5.27B | ¥4.34B | ¥5.10B | ¥6.60B |
| Total debt | ¥8.74B | ¥7.29B | ¥7.70B | ¥10.2B | ¥10.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3151.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.8% | -3.7% | 7th lowest of 21 |
| 6-month return | -1.4% | -5.6% | 9th highest of 21 |
| Distance from 52-week high | -17.7% | -22.4% | 8th highest of 21 |
| Revenue growth (TTM) | +2.7% | +3.9% | 10th lowest of 21 |
| Operating margin | 0.5% | 2.3% | 7th lowest of 21 |
| EV / Sales | 0.1× | 1.2× | cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 0.0% | 8th most demanding of 16 |
| Growth delivered (Del g) | +2.6% | +6.0% | 5th lowest of 16 |
| Hurdle (Req g minus delivered) | +2.1 pp | -5.3 pp | 5th most demanding of 16 |
| ROIC minus cost of capital | -3.2 pp | -0.2 pp | 9th lowest of 21 |
| Net debt / EBITDA | -1.7× | 1.5× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vital KSK 3151.T | Japan | $399M | -1% | +3% | 0% | 0.1× | 4.7% | +2.6% |
| Excelsior Medical 4104.TW | Taiwan | $404M | +5% | +11% | 8% | 1.4× | -1.2% | +5.7% |
| Shenzhen Neptunus Bioengineering 000078.SZ | China | $411M | -48% | -22% | -1% | 0.6× | 58.3% | -7.8% |
| Gongwin Biopharm 6617.TWO | Taiwan | $412M | +87% | +12% | -530% | 288.8× | n/a | n/a |
| Thalys Medical Technology 603716.SS | China | $446M | -33% | -43% | -18% | 4.3× | n/a | n/a |
| Shanghai Lily & Beauty Cosmetics 605136.SS | China | $449M | -28% | +5% | 2% | 1.1× | 21.1% | -18.1% |
| Shanghai Universal Biotech 301166.SZ | China | $337M | -15% | +15% | -4% | 1.0× | n/a | n/a |
| Nagaileben 7447.T | Japan | $319M | 0% | +1% | 21% | 1.6× | -12.7% | -0.4% |
| GKHT Medical Technology 301370.SZ | China | $525M | -24% | -11% | 1% | 0.7× | 13.1% | +7.5% |
| Rongfeng 000668.SZ | China | $297M | -32% | +61% | 14% | 4.8× | 9.6% | +30.0% |
| Shanghai New World 600628.SS | China | $573M | -10% | -2% | 6% | 2.1× | -1.6% | +1.0% |
| Arata 2733.T | Japan | $576M | -3% | +3% | 1% | 0.1× | -6.2% | +3.8% |
| Neuca NEU.WA | Poland | $795M | -9% | +8% | 2% | 0.3× | 5.3% | +8.1% |
| Shanghai Haohai Biological Technology 688366.SS | China | $878M | -24% | -9% | -2% | 1.8× | 16.9% | +13.2% |
| Entero Healthcare Solutions ENTERO.NS | India | $925M | +60% | +35% | 4% | 1.2× | 24.7% | +29.9% |
| Arjo ARJO-B.ST | Sweden | $974M | +42% | 0% | 8% | 1.3× | -1.0% | +3.9% |
| Guangxi LiuYao 603368.SS | China | $975M | +1% | +2% | 5% | 0.4× | -9.7% | +6.0% |
| Nanjing Pharmaceutical 600713.SS | China | $999M | -2% | +3% | 2% | 0.3× | n/a | n/a |
| Shanghai C and D INNOSTIC Medical Technology 301584.SZ | China | $1.06B | -33% | +8% | 3% | 0.5× | -2.7% | +17.9% |
| DocMorris DOCM.SW | Switzerland | $1.08B | +169% | +11% | -8% | 1.0× | n/a | n/a |
| AS ONE 7476.T | Japan | $1.10B | +25% | +10% | 12% | 1.3× | 0.0% | +6.3% |